Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLSTICE
2017-004059-22Phase 3Unknown
- Sponsor
- Servier
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in metastatic colorectal adenocarcinoma (mCRC) comparing trifluridine/tipiracil + bevacizumab with capecitabine + bevacizumab (2 arms). Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
trifluridine + tipiracilbevacizumabcapecitabine
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2017-004059-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004059-22.